A case study discusses a 69-year-old woman with a history of stable diabetes facing elevated HbA1c levels despite normal fasting glucose. Initial investigations, including a day curve test, reveal high postprandial glucose levels. The analysis leads to identifying iron deficiency anemia, prompting f

9 views • 22 slides

Guidelines recommend checking HbA1c and random plasma glucose levels at baseline for all cancer patients before initiating anti-cancer therapy. Regular monitoring of plasma glucose levels during treatment is essential, with specific actions based on glucose readings. Immediate referrals and treatmen

0 views • 4 slides

Cancer patients undergoing anti-cancer therapy need vigilant monitoring for hyperglycemia. Baseline HbA1c and random plasma glucose levels must be checked before initiating therapy. Regular glucose monitoring, symptom assessment, and ketone testing are crucial throughout treatment. Prompt referrals,

0 views • 4 slides

Dr. Kashif Ali leads primary care for Type 2 diabetes, while Dr. James Boyle oversees secondary care in NHS GGC. The data from December 2018 shows the number of Type 2 diabetes patients, their care processes, HbA1c levels, and BMI status. The Diabetes Quality Improvement and Outcome Measures aim to

0 views • 27 slides

In the Diabetes Collaborative Project 2015-2016, a random sample of 75 diabetic patients' records were queried monthly at each clinic site, with a total sample size of 450 patients reviewed monthly. Outreach activities were conducted based on sample data results. Metric goal variations were observed

0 views • 7 slides

Updated results from the ABCD Semaglutide audit show significant weight reductions at 6 months in GLP1RA-naive individuals, with no significant change at 12 months. Similarly, HbA1c reductions were greater at 6 months for GLP1RA-naive individuals compared to switch individuals, showing significant i

0 views • 9 slides